ADAMTS13 and thrombotic thrombocytopenic purpura: The main goal of the intense follow-up of TTP survivors is the avoidance of clinical relapse (30–50%) and relevant ischemic end-organ damage, which is achieved by regular ADAMTS13 activity measurements, anti-ADAMTS13 antibody levels (in iTTP) monitoring, and blood count and hemolysis parameters assessment.